Cholecystitis (HC Assoc. +VRE RFs)

Note

Duration of therapy after source control is 4-7d guided by resolution of fever, normal WBC, and benign abdomen.

Generally, longer duration of therapy for bacteremia.

Target therapy once biliary cultures available.

If no growth or no enterococcal growth discontinue enterococcal coverage (i.e. Linezolid or Daptomycin).

Linezolid 600mg PO/IV q12h

OR

Daptomycin 6mg/kg IV daily

AND EITHER

Piperacillin-tazobactam 3.375 gm IV q6h

OR

Meropenem 500 mg IV q6h or 1 gm IV q8h

Consider ID Consultation in the immunocompromised patient